

Notes:


- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2011.
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 As reported earlier, the outstanding of principal value of Foreign Currency Convertible Bonds(The Bond) of USD 43,999,000, which have become due for redemption with redemption premium of USD 19,887,548, has not been redeemed.
- 4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations
- 5 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 6 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.

Date: 12.08.2011

Visit us at www.marksanspharma.com

For MARKSANS PHARMA LIMITED



MARK SALDANHA
Managing Director.

